(Albany, US) DelveInsight has launched a new report on “Hypertriglyceridemia – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Hypertriglyceridemia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Hypertriglyceridemia, historical and forecasted epidemiology as well as the Hypertriglyceridemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the Facts
Request for Free Sample Report: https://www.delveinsight.com/sample-request/hypertriglyceridemia-market
Scope of the Report
Hypertriglyceridemia refers to a fasting plasma triglyceride measurement that is increased, typically above the 95th percentile for age and sex along with additional quantitative or qualitative lipoprotein abnormalities. Patients can fluctuate between hypertriglyceridemic states: given appropriate metabolic stress, mild or moderate hypertriglyceridemia can deteriorate into severe hypertriglyceridemia.
The two main sources of plasma triglycerides (also known as triacylglycerol) are exogenous (i.e., from dietary fat)— carried in chylomicrons, and endogenous (from the liver)—carried in very-low-density lipoprotein (VLDL) particles.
HTG can be divided into primary and secondary types. In primary HTG, chylomicrons normally are cleared rapidly from plasma by lipoprotein lipase with apolipoprotein (apo) C-II as a cofactor—familial chylomicronemia (hyperlipoproteinemia type 1, in the Fredrickson system) and primary mixed hyperlipidemia (type 5) are each characterized by the pathologic presence of chylomicrons after a 12–14 h period of fasting—whereas, in secondary HTG, obesity is probably the metabolic stressor most frequently associated with hypertriglyceridemia, although associations with poorly controlled type 2 diabetes and excessive alcohol consumption are also common (associated with a secondary cause/acquired).
Drugs Covered:
Some of the Companies:
Table of Contents:
1. Key Insights
2. Executive Summary of Hypertriglyceridemia
3. Competitive Intelligence Analysis for Hypertriglyceridemia
4. Hypertriglyceridemia: Market Overview at a Glance
5. Hypertriglyceridemia: Disease Background and Overview
6. Patient Journey
7. Hypertriglyceridemia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Hypertriglyceridemia Treatment
11. Marketed Products
12. Emerging Therapies
13. Hypertriglyceridemia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Hypertriglyceridemia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/hypertriglyceridemia-market
Why should you buy this report?
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/hypertriglyceridemia-market